A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight

Part of paid clinical trials in Cypress, California.

Sponsor
Novo Nordisk A/S
Study ID
NCT07710768
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • UBT251 — DRUG
    Administered subcutaneously.
  • Cocktail (Warfarin/Caffeine/Midazolam) — DRUG
    Administered orally.

Study Details

The purpose of this clinical study is to find out if UBT251 is safe and effective to be taken together with medicines, like midazolam, caffeine and warfarin in participants living with overweight or obesity.

Key Dates

First listed
Jul 17, 2026
Start date
Jul 15, 2026
Status verified
Aug 2026
Primary completion
Apr 7, 2027
Completion
Apr 7, 2027

Study Design

Enrollment
44 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: UBT251
    UBT251 will be administered subcutaneously with gradual dose escalation during the study.
  • Experimental: Cocktail (Warfarin/Caffeine/Midazolam)
    A cocktail containing warfarin, caffeine, and midazolam will be administered at predefined study visits to evaluate the effect of UBT251 on the pharmacokinetics of CYP enzyme substrates.

Primary Outcome Measure

AUC0-∞,s-warfarin: The area under the plasma s-warfarin concentration-time curve extrapolated to infinity after single dose [ Time Frame: From pre-dose on Day 1 up to 156 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Altasciences Clinical LA, Inc.CypressCalifornia90630-

Find similar trials in Cypress, CA

Nationwide
Obesity / overweight trialsEndocrinology trialsMetabolic health trialsWeight loss trials
By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Altasciences Clinical LA, Inc.· Cypress, CA

Related Studies